Glucose-Lowering Drugs May Reduce Risk of Developing Epilepsy

Ozempic may offer a surprising bonus benefit for brain health

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous long-term studies are needed to understand the link.

GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients

(MedPage Today) -- GLP-1 receptor agonists were tied to a lower risk of developing epilepsy in adults with type 2 diabetes, a large U.S. study showed. Compared with DPP-4 inhibitors, GLP-1 receptor agonist use was associated with a 16% lower risk...

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

Ozempic Shows a Possible Hidden Effect on Epilepsy Risk

GLP-1 drugs like Ozempic, Trulicity and Victoza were associated with a slightly lower likelihood of developing epilepsy in a large group of people with type 2 diabetes. GLP-1 drugs may be connected to a lower chance of developing epilepsy in people with type 2 diabetes, offering an intriguing early signal for researchers. Participants who used [...]

GLP-1 diabetes drugs linked to lower epilepsy risk in large study

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published in Neurology.